Dr. Reddy’s receives EIR from USFDA

Dr Reddy's Laboratories Ltd has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (FDA)

83
USFDA
Picture: Pixabay

Dr. Reddy’s receives EIR from USFDA

Dr Reddy’s Laboratories Ltd has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (FDA) for Srikakulam formulations plant unit I, indicating closure of the audit.

The inspection classification of this facility is determined as “No Action Indicated” (NAI). Dr Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Also read” EU GMP Certification for Biocon

The company’s therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.